nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—CYP2A6—Prednisolone—multiple sclerosis	0.0604	0.629	CbGbCtD
Ezogabine—NAT2—pineal body—multiple sclerosis	0.0562	0.273	CbGeAlD
Ezogabine—CYP2A6—Dexamethasone—multiple sclerosis	0.0356	0.371	CbGbCtD
Ezogabine—KCNQ4—Voltage gated Potassium channels—KCNA3—multiple sclerosis	0.0292	0.0896	CbGpPWpGaD
Ezogabine—KCNQ5—Voltage gated Potassium channels—KCNA3—multiple sclerosis	0.0292	0.0896	CbGpPWpGaD
Ezogabine—KCNQ3—Voltage gated Potassium channels—KCNA3—multiple sclerosis	0.0158	0.0484	CbGpPWpGaD
Ezogabine—KCNQ2—Voltage gated Potassium channels—KCNA3—multiple sclerosis	0.0158	0.0484	CbGpPWpGaD
Ezogabine—KCNQ4—Potassium Channels—KCNA3—multiple sclerosis	0.015	0.046	CbGpPWpGaD
Ezogabine—KCNQ5—Potassium Channels—KCNA3—multiple sclerosis	0.015	0.046	CbGpPWpGaD
Ezogabine—KCNQ4—retina—multiple sclerosis	0.0148	0.0718	CbGeAlD
Ezogabine—KCNQ5—retina—multiple sclerosis	0.0144	0.0699	CbGeAlD
Ezogabine—KCNQ2—brainstem—multiple sclerosis	0.011	0.0535	CbGeAlD
Ezogabine—KCNQ5—midbrain—multiple sclerosis	0.00951	0.0461	CbGeAlD
Ezogabine—KCNQ3—L1CAM interactions—CD24—multiple sclerosis	0.0093	0.0285	CbGpPWpGaD
Ezogabine—KCNQ2—L1CAM interactions—CD24—multiple sclerosis	0.0093	0.0285	CbGpPWpGaD
Ezogabine—KCNQ3—medulla oblongata—multiple sclerosis	0.00835	0.0405	CbGeAlD
Ezogabine—KCNQ3—Potassium Channels—KCNA3—multiple sclerosis	0.00809	0.0248	CbGpPWpGaD
Ezogabine—KCNQ2—Potassium Channels—KCNA3—multiple sclerosis	0.00809	0.0248	CbGpPWpGaD
Ezogabine—KCNQ5—nervous system—multiple sclerosis	0.00781	0.0379	CbGeAlD
Ezogabine—KCNQ3—midbrain—multiple sclerosis	0.00763	0.037	CbGeAlD
Ezogabine—KCNQ4—cerebellum—multiple sclerosis	0.00756	0.0367	CbGeAlD
Ezogabine—KCNQ5—central nervous system—multiple sclerosis	0.00752	0.0365	CbGeAlD
Ezogabine—KCNQ5—Neuronal System—KCNA3—multiple sclerosis	0.00654	0.0201	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—KCNA3—multiple sclerosis	0.00654	0.0201	CbGpPWpGaD
Ezogabine—KCNQ3—nervous system—multiple sclerosis	0.00627	0.0304	CbGeAlD
Ezogabine—KCNQ4—brain—multiple sclerosis	0.00614	0.0298	CbGeAlD
Ezogabine—KCNQ3—central nervous system—multiple sclerosis	0.00604	0.0293	CbGeAlD
Ezogabine—KCNQ5—brain—multiple sclerosis	0.00597	0.029	CbGeAlD
Ezogabine—KCNQ3—cerebellum—multiple sclerosis	0.0059	0.0286	CbGeAlD
Ezogabine—KCNQ2—nervous system—multiple sclerosis	0.00577	0.028	CbGeAlD
Ezogabine—KCNQ2—central nervous system—multiple sclerosis	0.00556	0.027	CbGeAlD
Ezogabine—KCNQ2—cerebellum—multiple sclerosis	0.00543	0.0264	CbGeAlD
Ezogabine—KCNQ3—brain—multiple sclerosis	0.00479	0.0233	CbGeAlD
Ezogabine—KCNQ2—brain—multiple sclerosis	0.00441	0.0214	CbGeAlD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.0043	0.0132	CbGpPWpGaD
Ezogabine—UGT1A9—Irinotecan Pathway—BCHE—multiple sclerosis	0.00402	0.0123	CbGpPWpGaD
Ezogabine—UGT1A1—Irinotecan Pathway—BCHE—multiple sclerosis	0.00402	0.0123	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.00357	0.011	CbGpPWpGaD
Ezogabine—NAT2—Biological oxidations—CYP27B1—multiple sclerosis	0.00356	0.0109	CbGpPWpGaD
Ezogabine—NAT2—Biological oxidations—CYP24A1—multiple sclerosis	0.00356	0.0109	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—KCNA3—multiple sclerosis	0.00353	0.0108	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—KCNA3—multiple sclerosis	0.00353	0.0108	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—CD24—multiple sclerosis	0.00352	0.0108	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—CD24—multiple sclerosis	0.00352	0.0108	CbGpPWpGaD
Ezogabine—NAT2—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00352	0.0108	CbGpPWpGaD
Ezogabine—NAT2—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00352	0.0108	CbGpPWpGaD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—RRM1—multiple sclerosis	0.00271	0.00833	CbGpPWpGaD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.0027	0.00828	CbGpPWpGaD
Ezogabine—CYP2A6—cerebellum—multiple sclerosis	0.0027	0.0131	CbGeAlD
Ezogabine—KCNQ3—Developmental Biology—CD24—multiple sclerosis	0.00251	0.0077	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—CD24—multiple sclerosis	0.00251	0.0077	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.00247	0.00757	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.00247	0.00757	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.00224	0.00688	CbGpPWpGaD
Ezogabine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00222	0.00681	CbGpPWpGaD
Ezogabine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00222	0.00681	CbGpPWpGaD
Ezogabine—CYP2A6—brain—multiple sclerosis	0.00219	0.0106	CbGeAlD
Ezogabine—CYP2A6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00219	0.00672	CbGpPWpGaD
Ezogabine—CYP2A6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00219	0.00672	CbGpPWpGaD
Ezogabine—UGT1A4—Biological oxidations—CYP27B1—multiple sclerosis	0.00216	0.00662	CbGpPWpGaD
Ezogabine—UGT1A4—Biological oxidations—CYP24A1—multiple sclerosis	0.00216	0.00662	CbGpPWpGaD
Ezogabine—UGT1A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00213	0.00653	CbGpPWpGaD
Ezogabine—UGT1A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00213	0.00653	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—BCHE—multiple sclerosis	0.00183	0.00563	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—BCHE—multiple sclerosis	0.00183	0.00563	CbGpPWpGaD
Ezogabine—CYP2A6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.0018	0.00552	CbGpPWpGaD
Ezogabine—CYP2A6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.0018	0.00552	CbGpPWpGaD
Ezogabine—UGT1A3—Biological oxidations—CYP24A1—multiple sclerosis	0.0018	0.00551	CbGpPWpGaD
Ezogabine—UGT1A3—Biological oxidations—CYP27B1—multiple sclerosis	0.0018	0.00551	CbGpPWpGaD
Ezogabine—UGT1A3—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00177	0.00543	CbGpPWpGaD
Ezogabine—UGT1A3—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00177	0.00543	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.00155	0.00476	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.00155	0.00476	CbGpPWpGaD
Ezogabine—Increased appetite—Dexamethasone—multiple sclerosis	0.00155	0.00416	CcSEcCtD
Ezogabine—Increased appetite—Betamethasone—multiple sclerosis	0.00155	0.00416	CcSEcCtD
Ezogabine—Dysarthria—Methotrexate—multiple sclerosis	0.00154	0.00414	CcSEcCtD
Ezogabine—Hyperhidrosis—Cladribine—multiple sclerosis	0.00153	0.00412	CcSEcCtD
Ezogabine—Euphoric mood—Prednisone—multiple sclerosis	0.0015	0.00403	CcSEcCtD
Ezogabine—Ill-defined disorder—Azathioprine—multiple sclerosis	0.00147	0.00394	CcSEcCtD
Ezogabine—Osteoarthritis—Dexamethasone—multiple sclerosis	0.00145	0.00391	CcSEcCtD
Ezogabine—Osteoarthritis—Betamethasone—multiple sclerosis	0.00145	0.00391	CcSEcCtD
Ezogabine—Malaise—Azathioprine—multiple sclerosis	0.00143	0.00383	CcSEcCtD
Ezogabine—Paraesthesia—Cladribine—multiple sclerosis	0.00142	0.00383	CcSEcCtD
Ezogabine—Psychotic disorder—Betamethasone—multiple sclerosis	0.00142	0.00382	CcSEcCtD
Ezogabine—Psychotic disorder—Dexamethasone—multiple sclerosis	0.00142	0.00382	CcSEcCtD
Ezogabine—Leukopenia—Azathioprine—multiple sclerosis	0.00142	0.00381	CcSEcCtD
Ezogabine—Dyspnoea—Cladribine—multiple sclerosis	0.00141	0.0038	CcSEcCtD
Ezogabine—Somnolence—Cladribine—multiple sclerosis	0.00141	0.00379	CcSEcCtD
Ezogabine—Influenza—Triamcinolone—multiple sclerosis	0.00138	0.00372	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.00137	0.00368	CcSEcCtD
Ezogabine—Weight increased—Prednisolone—multiple sclerosis	0.00137	0.00368	CcSEcCtD
Ezogabine—Fatigue—Cladribine—multiple sclerosis	0.00137	0.00368	CcSEcCtD
Ezogabine—Constipation—Cladribine—multiple sclerosis	0.00136	0.00365	CcSEcCtD
Ezogabine—Increased appetite—Prednisone—multiple sclerosis	0.00135	0.00362	CcSEcCtD
Ezogabine—Amnesia—Prednisone—multiple sclerosis	0.00135	0.00362	CcSEcCtD
Ezogabine—Coma—Methotrexate—multiple sclerosis	0.00133	0.00358	CcSEcCtD
Ezogabine—Discomfort—Azathioprine—multiple sclerosis	0.00133	0.00358	CcSEcCtD
Ezogabine—Feeling abnormal—Cladribine—multiple sclerosis	0.00131	0.00352	CcSEcCtD
Ezogabine—Alopecia—Mitoxantrone—multiple sclerosis	0.0013	0.00349	CcSEcCtD
Ezogabine—Infection—Azathioprine—multiple sclerosis	0.00128	0.00345	CcSEcCtD
Ezogabine—Osteoarthritis—Prednisone—multiple sclerosis	0.00127	0.0034	CcSEcCtD
Ezogabine—Thrombocytopenia—Azathioprine—multiple sclerosis	0.00126	0.0034	CcSEcCtD
Ezogabine—Weight increased—Triamcinolone—multiple sclerosis	0.00126	0.00339	CcSEcCtD
Ezogabine—Weight increased—Methylprednisolone—multiple sclerosis	0.00126	0.00338	CcSEcCtD
Ezogabine—UGT1A1—Biological oxidations—CYP24A1—multiple sclerosis	0.00124	0.0038	CbGpPWpGaD
Ezogabine—UGT1A1—Biological oxidations—CYP27B1—multiple sclerosis	0.00124	0.0038	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—CYP24A1—multiple sclerosis	0.00124	0.0038	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—CYP27B1—multiple sclerosis	0.00124	0.0038	CbGpPWpGaD
Ezogabine—Psychotic disorder—Prednisone—multiple sclerosis	0.00124	0.00332	CcSEcCtD
Ezogabine—Infestation—Methylprednisolone—multiple sclerosis	0.00123	0.00331	CcSEcCtD
Ezogabine—Infestation NOS—Methylprednisolone—multiple sclerosis	0.00123	0.00331	CcSEcCtD
Ezogabine—UGT1A1—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00122	0.00375	CbGpPWpGaD
Ezogabine—UGT1A1—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00122	0.00375	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00122	0.00375	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00122	0.00375	CbGpPWpGaD
Ezogabine—Vision blurred—Mitoxantrone—multiple sclerosis	0.0012	0.00324	CcSEcCtD
Ezogabine—Ill-defined disorder—Mitoxantrone—multiple sclerosis	0.00119	0.00319	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	0.00116	0.00356	CbGpPWpGaD
Ezogabine—Visual impairment—Prednisolone—multiple sclerosis	0.00116	0.00312	CcSEcCtD
Ezogabine—KCNQ2—Axon guidance—PRNP—multiple sclerosis	0.00116	0.00356	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—PRNP—multiple sclerosis	0.00116	0.00356	CbGpPWpGaD
Ezogabine—Malaise—Mitoxantrone—multiple sclerosis	0.00115	0.0031	CcSEcCtD
Ezogabine—Leukopenia—Mitoxantrone—multiple sclerosis	0.00114	0.00308	CcSEcCtD
Ezogabine—Weight increased—Dexamethasone—multiple sclerosis	0.00114	0.00307	CcSEcCtD
Ezogabine—Weight increased—Betamethasone—multiple sclerosis	0.00114	0.00307	CcSEcCtD
Ezogabine—Asthenia—Cladribine—multiple sclerosis	0.00114	0.00306	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.00111	0.003	CcSEcCtD
Ezogabine—Hallucination—Methylprednisolone—multiple sclerosis	0.0011	0.00296	CcSEcCtD
Ezogabine—Anxiety—Mitoxantrone—multiple sclerosis	0.00108	0.00292	CcSEcCtD
Ezogabine—Discomfort—Mitoxantrone—multiple sclerosis	0.00108	0.00289	CcSEcCtD
Ezogabine—Visual impairment—Methylprednisolone—multiple sclerosis	0.00107	0.00286	CcSEcCtD
Ezogabine—Feeling abnormal—Azathioprine—multiple sclerosis	0.00106	0.00286	CcSEcCtD
Ezogabine—Osteoarthritis—Methotrexate—multiple sclerosis	0.00106	0.00284	CcSEcCtD
Ezogabine—Confusional state—Mitoxantrone—multiple sclerosis	0.00105	0.00283	CcSEcCtD
Ezogabine—Dizziness—Cladribine—multiple sclerosis	0.00105	0.00282	CcSEcCtD
Ezogabine—Infection—Mitoxantrone—multiple sclerosis	0.00104	0.00279	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	0.00104	0.00318	CbGpPWpGaD
Ezogabine—Eye disorder—Methylprednisolone—multiple sclerosis	0.00103	0.00278	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	0.00103	0.00316	CbGpPWpGaD
Ezogabine—Shock—Mitoxantrone—multiple sclerosis	0.00103	0.00276	CcSEcCtD
Ezogabine—Neutropenia—Prednisone—multiple sclerosis	0.00102	0.00275	CcSEcCtD
Ezogabine—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.00102	0.00275	CcSEcCtD
Ezogabine—Hyperhidrosis—Mitoxantrone—multiple sclerosis	0.00101	0.00271	CcSEcCtD
Ezogabine—Rash—Cladribine—multiple sclerosis	0.001	0.00269	CcSEcCtD
Ezogabine—Hallucination—Betamethasone—multiple sclerosis	0.001	0.00269	CcSEcCtD
Ezogabine—Hallucination—Dexamethasone—multiple sclerosis	0.001	0.00269	CcSEcCtD
Ezogabine—Dermatitis—Cladribine—multiple sclerosis	0.001	0.00269	CcSEcCtD
Ezogabine—Weight increased—Prednisone—multiple sclerosis	0.000995	0.00268	CcSEcCtD
Ezogabine—KCNQ3—Neuronal System—BCHE—multiple sclerosis	0.000991	0.00304	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—BCHE—multiple sclerosis	0.000991	0.00304	CbGpPWpGaD
Ezogabine—Vision blurred—Prednisolone—multiple sclerosis	0.000988	0.00266	CcSEcCtD
Ezogabine—Liver function test abnormal—Methotrexate—multiple sclerosis	0.000976	0.00262	CcSEcCtD
Ezogabine—Ill-defined disorder—Prednisolone—multiple sclerosis	0.000973	0.00262	CcSEcCtD
Ezogabine—Visual impairment—Betamethasone—multiple sclerosis	0.000969	0.0026	CcSEcCtD
Ezogabine—Visual impairment—Dexamethasone—multiple sclerosis	0.000969	0.0026	CcSEcCtD
Ezogabine—Mental disorder—Methylprednisolone—multiple sclerosis	0.000968	0.0026	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	0.000965	0.00296	CbGpPWpGaD
Ezogabine—Malnutrition—Methylprednisolone—multiple sclerosis	0.000962	0.00259	CcSEcCtD
Ezogabine—CYP2A6—Biological oxidations—CYP24A1—multiple sclerosis	0.000956	0.00293	CbGpPWpGaD
Ezogabine—CYP2A6—Biological oxidations—CYP27B1—multiple sclerosis	0.000956	0.00293	CbGpPWpGaD
Ezogabine—Malaise—Prednisolone—multiple sclerosis	0.000946	0.00254	CcSEcCtD
Ezogabine—Nausea—Cladribine—multiple sclerosis	0.000943	0.00253	CcSEcCtD
Ezogabine—Vertigo—Prednisolone—multiple sclerosis	0.000942	0.00253	CcSEcCtD
Ezogabine—Syncope—Prednisolone—multiple sclerosis	0.00094	0.00253	CcSEcCtD
Ezogabine—Eye disorder—Betamethasone—multiple sclerosis	0.000939	0.00253	CcSEcCtD
Ezogabine—Eye disorder—Dexamethasone—multiple sclerosis	0.000939	0.00253	CcSEcCtD
Ezogabine—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000937	0.00252	CcSEcCtD
Ezogabine—Dyspnoea—Mitoxantrone—multiple sclerosis	0.00093	0.0025	CcSEcCtD
Ezogabine—Somnolence—Mitoxantrone—multiple sclerosis	0.000927	0.00249	CcSEcCtD
Ezogabine—Loss of consciousness—Prednisolone—multiple sclerosis	0.000922	0.00248	CcSEcCtD
Ezogabine—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000918	0.00247	CcSEcCtD
Ezogabine—KCNQ3—Axon guidance—PTPRC—multiple sclerosis	0.000902	0.00277	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—PTPRC—multiple sclerosis	0.000902	0.00277	CbGpPWpGaD
Ezogabine—Fatigue—Mitoxantrone—multiple sclerosis	0.000899	0.00242	CcSEcCtD
Ezogabine—Ill-defined disorder—Triamcinolone—multiple sclerosis	0.000895	0.00241	CcSEcCtD
Ezogabine—Ill-defined disorder—Methylprednisolone—multiple sclerosis	0.000893	0.0024	CcSEcCtD
Ezogabine—Constipation—Mitoxantrone—multiple sclerosis	0.000892	0.0024	CcSEcCtD
Ezogabine—Alopecia—Betamethasone—multiple sclerosis	0.000888	0.00239	CcSEcCtD
Ezogabine—Alopecia—Dexamethasone—multiple sclerosis	0.000888	0.00239	CcSEcCtD
Ezogabine—Discomfort—Prednisolone—multiple sclerosis	0.000882	0.00237	CcSEcCtD
Ezogabine—Hallucination—Prednisone—multiple sclerosis	0.000871	0.00234	CcSEcCtD
Ezogabine—Malaise—Triamcinolone—multiple sclerosis	0.00087	0.00234	CcSEcCtD
Ezogabine—Malaise—Methylprednisolone—multiple sclerosis	0.000868	0.00233	CcSEcCtD
Ezogabine—Vertigo—Triamcinolone—multiple sclerosis	0.000866	0.00233	CcSEcCtD
Ezogabine—NAT2—Metabolism—SRM—multiple sclerosis	0.000865	0.00265	CbGpPWpGaD
Ezogabine—Syncope—Triamcinolone—multiple sclerosis	0.000865	0.00233	CcSEcCtD
Ezogabine—Vertigo—Methylprednisolone—multiple sclerosis	0.000864	0.00232	CcSEcCtD
Ezogabine—Syncope—Methylprednisolone—multiple sclerosis	0.000863	0.00232	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	0.000861	0.00264	CbGpPWpGaD
Ezogabine—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.00086	0.00231	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	0.000858	0.00263	CbGpPWpGaD
Ezogabine—Dysuria—Methotrexate—multiple sclerosis	0.000855	0.0023	CcSEcCtD
Ezogabine—Neutropenia—Methotrexate—multiple sclerosis	0.000855	0.0023	CcSEcCtD
Ezogabine—Dizziness—Azathioprine—multiple sclerosis	0.000853	0.00229	CcSEcCtD
Ezogabine—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000847	0.00228	CcSEcCtD
Ezogabine—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000846	0.00227	CcSEcCtD
Ezogabine—Shock—Prednisolone—multiple sclerosis	0.000842	0.00226	CcSEcCtD
Ezogabine—KCNQ2—Developmental Biology—PRNP—multiple sclerosis	0.000828	0.00254	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—PRNP—multiple sclerosis	0.000828	0.00254	CbGpPWpGaD
Ezogabine—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000827	0.00222	CcSEcCtD
Ezogabine—Eye disorder—Prednisone—multiple sclerosis	0.000818	0.0022	CcSEcCtD
Ezogabine—Anxiety—Methylprednisolone—multiple sclerosis	0.000816	0.00219	CcSEcCtD
Ezogabine—Infestation NOS—Methotrexate—multiple sclerosis	0.000815	0.00219	CcSEcCtD
Ezogabine—Infestation—Methotrexate—multiple sclerosis	0.000815	0.00219	CcSEcCtD
Ezogabine—Rash—Azathioprine—multiple sclerosis	0.000814	0.00219	CcSEcCtD
Ezogabine—Dermatitis—Azathioprine—multiple sclerosis	0.000813	0.00219	CcSEcCtD
Ezogabine—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000812	0.00218	CcSEcCtD
Ezogabine—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000812	0.00218	CcSEcCtD
Ezogabine—Discomfort—Triamcinolone—multiple sclerosis	0.000811	0.00218	CcSEcCtD
Ezogabine—Discomfort—Methylprednisolone—multiple sclerosis	0.000809	0.00218	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000805	0.00247	CbGpPWpGaD
Ezogabine—Dry mouth—Triamcinolone—multiple sclerosis	0.000803	0.00216	CcSEcCtD
Ezogabine—NAT2—Biological oxidations—POMC—multiple sclerosis	0.000802	0.00246	CbGpPWpGaD
Ezogabine—Confusional state—Methylprednisolone—multiple sclerosis	0.000792	0.00213	CcSEcCtD
Ezogabine—Malaise—Dexamethasone—multiple sclerosis	0.000789	0.00212	CcSEcCtD
Ezogabine—Malaise—Betamethasone—multiple sclerosis	0.000789	0.00212	CcSEcCtD
Ezogabine—Vertigo—Betamethasone—multiple sclerosis	0.000786	0.00211	CcSEcCtD
Ezogabine—Vertigo—Dexamethasone—multiple sclerosis	0.000786	0.00211	CcSEcCtD
Ezogabine—Syncope—Dexamethasone—multiple sclerosis	0.000785	0.00211	CcSEcCtD
Ezogabine—Syncope—Betamethasone—multiple sclerosis	0.000785	0.00211	CcSEcCtD
Ezogabine—Infection—Triamcinolone—multiple sclerosis	0.000782	0.0021	CcSEcCtD
Ezogabine—Infection—Methylprednisolone—multiple sclerosis	0.00078	0.0021	CcSEcCtD
Ezogabine—Haematuria—Methotrexate—multiple sclerosis	0.000777	0.00209	CcSEcCtD
Ezogabine—Shock—Triamcinolone—multiple sclerosis	0.000774	0.00208	CcSEcCtD
Ezogabine—Alopecia—Prednisone—multiple sclerosis	0.000773	0.00208	CcSEcCtD
Ezogabine—Shock—Methylprednisolone—multiple sclerosis	0.000772	0.00208	CcSEcCtD
Ezogabine—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000771	0.00207	CcSEcCtD
Ezogabine—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.00077	0.00207	CcSEcCtD
Ezogabine—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000769	0.00207	CcSEcCtD
Ezogabine—Loss of consciousness—Betamethasone—multiple sclerosis	0.000769	0.00207	CcSEcCtD
Ezogabine—Paraesthesia—Prednisolone—multiple sclerosis	0.000768	0.00207	CcSEcCtD
Ezogabine—Mental disorder—Prednisone—multiple sclerosis	0.000767	0.00206	CcSEcCtD
Ezogabine—Nausea—Azathioprine—multiple sclerosis	0.000766	0.00206	CcSEcCtD
Ezogabine—Malnutrition—Prednisone—multiple sclerosis	0.000762	0.00205	CcSEcCtD
Ezogabine—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000761	0.00205	CcSEcCtD
Ezogabine—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000759	0.00204	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	0.000751	0.0023	CbGpPWpGaD
Ezogabine—Asthenia—Mitoxantrone—multiple sclerosis	0.000748	0.00201	CcSEcCtD
Ezogabine—Anxiety—Betamethasone—multiple sclerosis	0.000742	0.002	CcSEcCtD
Ezogabine—Anxiety—Dexamethasone—multiple sclerosis	0.000742	0.002	CcSEcCtD
Ezogabine—Discomfort—Dexamethasone—multiple sclerosis	0.000736	0.00198	CcSEcCtD
Ezogabine—Discomfort—Betamethasone—multiple sclerosis	0.000736	0.00198	CcSEcCtD
Ezogabine—UGT1A9—PPAR Alpha Pathway—MYC—multiple sclerosis	0.000731	0.00224	CbGpPWpGaD
Ezogabine—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000722	0.00194	CcSEcCtD
Ezogabine—Vision blurred—Prednisone—multiple sclerosis	0.000718	0.00193	CcSEcCtD
Ezogabine—Urethral disorder—Methotrexate—multiple sclerosis	0.000717	0.00193	CcSEcCtD
Ezogabine—Infection—Dexamethasone—multiple sclerosis	0.000709	0.00191	CcSEcCtD
Ezogabine—Infection—Betamethasone—multiple sclerosis	0.000709	0.00191	CcSEcCtD
Ezogabine—Ill-defined disorder—Prednisone—multiple sclerosis	0.000707	0.0019	CcSEcCtD
Ezogabine—Paraesthesia—Triamcinolone—multiple sclerosis	0.000707	0.0019	CcSEcCtD
Ezogabine—Feeling abnormal—Prednisolone—multiple sclerosis	0.000705	0.0019	CcSEcCtD
Ezogabine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000705	0.0019	CcSEcCtD
Ezogabine—Visual impairment—Methotrexate—multiple sclerosis	0.000705	0.0019	CcSEcCtD
Ezogabine—Shock—Dexamethasone—multiple sclerosis	0.000702	0.00189	CcSEcCtD
Ezogabine—Shock—Betamethasone—multiple sclerosis	0.000702	0.00189	CcSEcCtD
Ezogabine—Dyspnoea—Triamcinolone—multiple sclerosis	0.000702	0.00189	CcSEcCtD
Ezogabine—Nervous system disorder—Betamethasone—multiple sclerosis	0.0007	0.00188	CcSEcCtD
Ezogabine—Nervous system disorder—Dexamethasone—multiple sclerosis	0.0007	0.00188	CcSEcCtD
Ezogabine—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000699	0.00188	CcSEcCtD
Ezogabine—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000699	0.00188	CcSEcCtD
Ezogabine—Dyspepsia—Triamcinolone—multiple sclerosis	0.000693	0.00186	CcSEcCtD
Ezogabine—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000691	0.00186	CcSEcCtD
Ezogabine—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.00069	0.00186	CcSEcCtD
Ezogabine—Hyperhidrosis—Betamethasone—multiple sclerosis	0.00069	0.00186	CcSEcCtD
Ezogabine—Malaise—Prednisone—multiple sclerosis	0.000687	0.00185	CcSEcCtD
Ezogabine—Vertigo—Prednisone—multiple sclerosis	0.000685	0.00184	CcSEcCtD
Ezogabine—Eye disorder—Methotrexate—multiple sclerosis	0.000684	0.00184	CcSEcCtD
Ezogabine—Syncope—Prednisone—multiple sclerosis	0.000683	0.00184	CcSEcCtD
Ezogabine—KCNQ2—L1CAM interactions—MAPK1—multiple sclerosis	0.00068	0.00209	CbGpPWpGaD
Ezogabine—KCNQ3—L1CAM interactions—MAPK1—multiple sclerosis	0.00068	0.00209	CbGpPWpGaD
Ezogabine—Fatigue—Triamcinolone—multiple sclerosis	0.000678	0.00182	CcSEcCtD
Ezogabine—Fatigue—Methylprednisolone—multiple sclerosis	0.000677	0.00182	CcSEcCtD
Ezogabine—Loss of consciousness—Prednisone—multiple sclerosis	0.00067	0.0018	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000669	0.00205	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	0.000667	0.00205	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	0.000667	0.00205	CbGpPWpGaD
Ezogabine—Rash—Mitoxantrone—multiple sclerosis	0.000658	0.00177	CcSEcCtD
Ezogabine—Dermatitis—Mitoxantrone—multiple sclerosis	0.000657	0.00177	CcSEcCtD
Ezogabine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000648	0.00174	CcSEcCtD
Ezogabine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000647	0.00174	CcSEcCtD
Ezogabine—Anxiety—Prednisone—multiple sclerosis	0.000646	0.00174	CcSEcCtD
Ezogabine—Alopecia—Methotrexate—multiple sclerosis	0.000646	0.00174	CcSEcCtD
Ezogabine—KCNQ3—Developmental Biology—PTPRC—multiple sclerosis	0.000644	0.00197	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—PTPRC—multiple sclerosis	0.000644	0.00197	CbGpPWpGaD
Ezogabine—Paraesthesia—Betamethasone—multiple sclerosis	0.000641	0.00172	CcSEcCtD
Ezogabine—Paraesthesia—Dexamethasone—multiple sclerosis	0.000641	0.00172	CcSEcCtD
Ezogabine—Discomfort—Prednisone—multiple sclerosis	0.000641	0.00172	CcSEcCtD
Ezogabine—Mental disorder—Methotrexate—multiple sclerosis	0.000641	0.00172	CcSEcCtD
Ezogabine—Malnutrition—Methotrexate—multiple sclerosis	0.000637	0.00171	CcSEcCtD
Ezogabine—Dyspepsia—Betamethasone—multiple sclerosis	0.000629	0.00169	CcSEcCtD
Ezogabine—Dyspepsia—Dexamethasone—multiple sclerosis	0.000629	0.00169	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	0.000625	0.00192	CbGpPWpGaD
Ezogabine—Nausea—Mitoxantrone—multiple sclerosis	0.00062	0.00167	CcSEcCtD
Ezogabine—Infection—Prednisone—multiple sclerosis	0.000618	0.00166	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000616	0.00166	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000616	0.00166	CcSEcCtD
Ezogabine—Fatigue—Betamethasone—multiple sclerosis	0.000616	0.00166	CcSEcCtD
Ezogabine—Fatigue—Dexamethasone—multiple sclerosis	0.000616	0.00166	CcSEcCtD
Ezogabine—Shock—Prednisone—multiple sclerosis	0.000612	0.00165	CcSEcCtD
Ezogabine—Nervous system disorder—Prednisone—multiple sclerosis	0.00061	0.00164	CcSEcCtD
Ezogabine—NAT2—Metabolism—CYP27B1—multiple sclerosis	0.00061	0.00187	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CYP24A1—multiple sclerosis	0.00061	0.00187	CbGpPWpGaD
Ezogabine—Hyperhidrosis—Prednisone—multiple sclerosis	0.000601	0.00162	CcSEcCtD
Ezogabine—Vision blurred—Methotrexate—multiple sclerosis	0.0006	0.00161	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	0.000595	0.00182	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	0.000595	0.00182	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	0.000592	0.00182	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	0.000592	0.00182	CbGpPWpGaD
Ezogabine—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000591	0.00159	CcSEcCtD
Ezogabine—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000588	0.00158	CcSEcCtD
Ezogabine—Feeling abnormal—Betamethasone—multiple sclerosis	0.000588	0.00158	CcSEcCtD
Ezogabine—Malaise—Methotrexate—multiple sclerosis	0.000574	0.00154	CcSEcCtD
Ezogabine—Vertigo—Methotrexate—multiple sclerosis	0.000572	0.00154	CcSEcCtD
Ezogabine—Leukopenia—Methotrexate—multiple sclerosis	0.00057	0.00153	CcSEcCtD
Ezogabine—Dizziness—Prednisolone—multiple sclerosis	0.000566	0.00152	CcSEcCtD
Ezogabine—Asthenia—Triamcinolone—multiple sclerosis	0.000565	0.00152	CcSEcCtD
Ezogabine—Asthenia—Methylprednisolone—multiple sclerosis	0.000563	0.00151	CcSEcCtD
Ezogabine—Paraesthesia—Prednisone—multiple sclerosis	0.000558	0.0015	CcSEcCtD
Ezogabine—NAT2—Metabolism—GPC5—multiple sclerosis	0.000558	0.00171	CbGpPWpGaD
Ezogabine—Dyspepsia—Prednisone—multiple sclerosis	0.000547	0.00147	CcSEcCtD
Ezogabine—Rash—Prednisolone—multiple sclerosis	0.00054	0.00145	CcSEcCtD
Ezogabine—Dermatitis—Prednisolone—multiple sclerosis	0.000539	0.00145	CcSEcCtD
Ezogabine—KCNQ5—Neuronal System—MAPK1—multiple sclerosis	0.000536	0.00164	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—MAPK1—multiple sclerosis	0.000536	0.00164	CbGpPWpGaD
Ezogabine—Fatigue—Prednisone—multiple sclerosis	0.000536	0.00144	CcSEcCtD
Ezogabine—Discomfort—Methotrexate—multiple sclerosis	0.000536	0.00144	CcSEcCtD
Ezogabine—Constipation—Prednisone—multiple sclerosis	0.000532	0.00143	CcSEcCtD
Ezogabine—UGT1A4—Metabolism—SRM—multiple sclerosis	0.000524	0.00161	CbGpPWpGaD
Ezogabine—Confusional state—Methotrexate—multiple sclerosis	0.000524	0.00141	CcSEcCtD
Ezogabine—Dizziness—Triamcinolone—multiple sclerosis	0.00052	0.0014	CcSEcCtD
Ezogabine—Dizziness—Methylprednisolone—multiple sclerosis	0.000519	0.0014	CcSEcCtD
Ezogabine—Infection—Methotrexate—multiple sclerosis	0.000516	0.00139	CcSEcCtD
Ezogabine—Feeling abnormal—Prednisone—multiple sclerosis	0.000512	0.00138	CcSEcCtD
Ezogabine—Asthenia—Betamethasone—multiple sclerosis	0.000512	0.00138	CcSEcCtD
Ezogabine—Asthenia—Dexamethasone—multiple sclerosis	0.000512	0.00138	CcSEcCtD
Ezogabine—Nervous system disorder—Methotrexate—multiple sclerosis	0.00051	0.00137	CcSEcCtD
Ezogabine—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000509	0.00137	CcSEcCtD
Ezogabine—Nausea—Prednisolone—multiple sclerosis	0.000508	0.00137	CcSEcCtD
Ezogabine—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000502	0.00135	CcSEcCtD
Ezogabine—CYP2A6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.0005	0.00153	CbGpPWpGaD
Ezogabine—Rash—Triamcinolone—multiple sclerosis	0.000496	0.00133	CcSEcCtD
Ezogabine—Dermatitis—Triamcinolone—multiple sclerosis	0.000496	0.00133	CcSEcCtD
Ezogabine—Rash—Methylprednisolone—multiple sclerosis	0.000495	0.00133	CcSEcCtD
Ezogabine—Dermatitis—Methylprednisolone—multiple sclerosis	0.000495	0.00133	CcSEcCtD
Ezogabine—UGT1A4—Biological oxidations—POMC—multiple sclerosis	0.000486	0.00149	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000476	0.00146	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000476	0.00146	CbGpPWpGaD
Ezogabine—Dizziness—Dexamethasone—multiple sclerosis	0.000472	0.00127	CcSEcCtD
Ezogabine—Dizziness—Betamethasone—multiple sclerosis	0.000472	0.00127	CcSEcCtD
Ezogabine—Nausea—Triamcinolone—multiple sclerosis	0.000467	0.00126	CcSEcCtD
Ezogabine—Paraesthesia—Methotrexate—multiple sclerosis	0.000467	0.00125	CcSEcCtD
Ezogabine—Nausea—Methylprednisolone—multiple sclerosis	0.000466	0.00125	CcSEcCtD
Ezogabine—Dyspnoea—Methotrexate—multiple sclerosis	0.000463	0.00125	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000462	0.00142	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000462	0.00142	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—RRM1—multiple sclerosis	0.000462	0.00142	CbGpPWpGaD
Ezogabine—Somnolence—Methotrexate—multiple sclerosis	0.000462	0.00124	CcSEcCtD
Ezogabine—Dyspepsia—Methotrexate—multiple sclerosis	0.000457	0.00123	CcSEcCtD
Ezogabine—Rash—Dexamethasone—multiple sclerosis	0.00045	0.00121	CcSEcCtD
Ezogabine—Rash—Betamethasone—multiple sclerosis	0.00045	0.00121	CcSEcCtD
Ezogabine—Dermatitis—Dexamethasone—multiple sclerosis	0.00045	0.00121	CcSEcCtD
Ezogabine—Dermatitis—Betamethasone—multiple sclerosis	0.00045	0.00121	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000449	0.00121	CcSEcCtD
Ezogabine—Fatigue—Methotrexate—multiple sclerosis	0.000448	0.0012	CcSEcCtD
Ezogabine—Asthenia—Prednisone—multiple sclerosis	0.000446	0.0012	CcSEcCtD
Ezogabine—UGT1A3—Metabolism—SRM—multiple sclerosis	0.000436	0.00134	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	0.000432	0.00132	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	0.000432	0.00132	CbGpPWpGaD
Ezogabine—Feeling abnormal—Methotrexate—multiple sclerosis	0.000428	0.00115	CcSEcCtD
Ezogabine—Nausea—Betamethasone—multiple sclerosis	0.000424	0.00114	CcSEcCtD
Ezogabine—Nausea—Dexamethasone—multiple sclerosis	0.000424	0.00114	CcSEcCtD
Ezogabine—Dizziness—Prednisone—multiple sclerosis	0.000411	0.00111	CcSEcCtD
Ezogabine—CYP2A6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000405	0.00124	CbGpPWpGaD
Ezogabine—UGT1A3—Biological oxidations—POMC—multiple sclerosis	0.000404	0.00124	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—TYK2—multiple sclerosis	0.000404	0.00124	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—TYK2—multiple sclerosis	0.000404	0.00124	CbGpPWpGaD
Ezogabine—Rash—Prednisone—multiple sclerosis	0.000392	0.00105	CcSEcCtD
Ezogabine—Dermatitis—Prednisone—multiple sclerosis	0.000392	0.00105	CcSEcCtD
Ezogabine—Asthenia—Methotrexate—multiple sclerosis	0.000373	0.001	CcSEcCtD
Ezogabine—Nausea—Prednisone—multiple sclerosis	0.000369	0.000993	CcSEcCtD
Ezogabine—UGT1A4—Metabolism—CYP27B1—multiple sclerosis	0.000369	0.00113	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CYP24A1—multiple sclerosis	0.000369	0.00113	CbGpPWpGaD
Ezogabine—Dizziness—Methotrexate—multiple sclerosis	0.000344	0.000924	CcSEcCtD
Ezogabine—UGT1A4—Metabolism—GPC5—multiple sclerosis	0.000338	0.00104	CbGpPWpGaD
Ezogabine—Rash—Methotrexate—multiple sclerosis	0.000328	0.000881	CcSEcCtD
Ezogabine—Dermatitis—Methotrexate—multiple sclerosis	0.000327	0.00088	CcSEcCtD
Ezogabine—UGT1A4—NRF2 pathway—TGFB1—multiple sclerosis	0.000319	0.00098	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—MMP9—multiple sclerosis	0.000318	0.000975	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—MMP9—multiple sclerosis	0.000318	0.000975	CbGpPWpGaD
Ezogabine—Nausea—Methotrexate—multiple sclerosis	0.000309	0.00083	CcSEcCtD
Ezogabine—UGT1A3—Metabolism—CYP27B1—multiple sclerosis	0.000307	0.000942	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CYP24A1—multiple sclerosis	0.000307	0.000942	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—SRM—multiple sclerosis	0.000301	0.000923	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—SRM—multiple sclerosis	0.000301	0.000923	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—MAPK1—multiple sclerosis	0.00029	0.000888	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—MAPK1—multiple sclerosis	0.00029	0.000888	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—TYK2—multiple sclerosis	0.000288	0.000883	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—TYK2—multiple sclerosis	0.000288	0.000883	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GPC5—multiple sclerosis	0.000281	0.000861	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—RRM1—multiple sclerosis	0.00028	0.000859	CbGpPWpGaD
Ezogabine—UGT1A1—Biological oxidations—POMC—multiple sclerosis	0.000279	0.000856	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—POMC—multiple sclerosis	0.000279	0.000856	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—TGFB1—multiple sclerosis	0.000266	0.000814	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—BCHE—multiple sclerosis	0.000265	0.000814	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—MAPK1—multiple sclerosis	0.000257	0.000788	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—MAPK1—multiple sclerosis	0.000257	0.000788	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—RRM1—multiple sclerosis	0.000233	0.000714	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SRM—multiple sclerosis	0.000232	0.000712	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—MMP9—multiple sclerosis	0.000227	0.000696	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—MMP9—multiple sclerosis	0.000227	0.000696	CbGpPWpGaD
Ezogabine—CYP2A6—Biological oxidations—POMC—multiple sclerosis	0.000215	0.00066	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP24A1—multiple sclerosis	0.000212	0.000651	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP24A1—multiple sclerosis	0.000212	0.000651	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP27B1—multiple sclerosis	0.000212	0.000651	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP27B1—multiple sclerosis	0.000212	0.000651	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000207	0.000636	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—STAT3—multiple sclerosis	0.000202	0.000619	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—STAT3—multiple sclerosis	0.000202	0.000619	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—IL6—multiple sclerosis	0.000197	0.000605	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—IL6—multiple sclerosis	0.000197	0.000605	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GPC5—multiple sclerosis	0.000194	0.000595	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GPC5—multiple sclerosis	0.000194	0.000595	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—TGFB1—multiple sclerosis	0.000187	0.000573	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—TGFB1—multiple sclerosis	0.000187	0.000573	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—TGFB1—multiple sclerosis	0.000183	0.000563	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—TGFB1—multiple sclerosis	0.000183	0.000563	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—MAPK1—multiple sclerosis	0.000183	0.000562	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—MAPK1—multiple sclerosis	0.000183	0.000562	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—TNF—multiple sclerosis	0.000175	0.000535	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—TNF—multiple sclerosis	0.000175	0.000535	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP27B1—multiple sclerosis	0.000164	0.000502	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP24A1—multiple sclerosis	0.000164	0.000502	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—BCHE—multiple sclerosis	0.000161	0.000493	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—RRM1—multiple sclerosis	0.000161	0.000493	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—RRM1—multiple sclerosis	0.000161	0.000493	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—APOE—multiple sclerosis	0.00016	0.00049	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GPC5—multiple sclerosis	0.00015	0.000459	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—TGFB1—multiple sclerosis	0.000141	0.000434	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—IL6—multiple sclerosis	0.000141	0.000432	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—IL6—multiple sclerosis	0.000141	0.000432	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—POMC—multiple sclerosis	0.000137	0.000421	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—BCHE—multiple sclerosis	0.000134	0.00041	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—ALB—multiple sclerosis	0.000125	0.000383	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000125	0.000383	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—RRM1—multiple sclerosis	0.000124	0.00038	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	0.000107	0.000329	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	9.77e-05	0.0003	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—APOE—multiple sclerosis	9.67e-05	0.000297	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—BCHE—multiple sclerosis	9.23e-05	0.000283	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—BCHE—multiple sclerosis	9.23e-05	0.000283	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—POMC—multiple sclerosis	8.31e-05	0.000255	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—APOE—multiple sclerosis	8.04e-05	0.000247	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ALB—multiple sclerosis	7.57e-05	0.000232	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—BCHE—multiple sclerosis	7.12e-05	0.000218	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—POMC—multiple sclerosis	6.91e-05	0.000212	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ALB—multiple sclerosis	6.3e-05	0.000193	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—APOE—multiple sclerosis	5.55e-05	0.00017	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—APOE—multiple sclerosis	5.55e-05	0.00017	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—POMC—multiple sclerosis	4.77e-05	0.000146	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—POMC—multiple sclerosis	4.77e-05	0.000146	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ALB—multiple sclerosis	4.35e-05	0.000133	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ALB—multiple sclerosis	4.35e-05	0.000133	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—APOE—multiple sclerosis	4.28e-05	0.000131	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—POMC—multiple sclerosis	3.68e-05	0.000113	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ALB—multiple sclerosis	3.35e-05	0.000103	CbGpPWpGaD
